KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS-HF.

Toru Kondo, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Akshay S Desai, Meike Brinker, James Lay-Flurrie, Patrick Schloemer, Prabhakar Viswanathan, Flaviana Amarante, Chern-En Chiang, Gerasimos Filippatos, Carolyn S P Lam, Mark C Petrie, Michele Senni, Morten Schou, Subodh Verma, Adriaan A Voors, Dirk von Lewinski, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D Solomon, John J V McMurray

Eur J Heart Fail 27(8) 1459-1471

PMID40300840
PMCIDPMC12482849
DOI10.1002/ejhf.3669
发表日期2025-04-29
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:森林图/亚组分析图。
摘要

摘要

AIMS: FINEARTS-HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and mildly reduced or preserved ejection fraction. We examined the effect of finerenone on these events according to their clinical importance using win statistics. METHODS AND RESULTS: We developed a prespecified hierarchical composite endpoint including the components of the original primary outcome: cardiovascular death (tier 1), total HF hospitalizations (tier 2), and total urgent HF visits (tier 3). For tiers 2 and 3, the number of events was analysed first, followed by the time-to-first event. Because win statistics are affected by the censoring distribution, we assessed the hierarchical composite outcome over a fixed period of 24 months. The 6001 participants analysed were randomized equally to finerenone (n = 3003) or placebo (n = 2998). At 24 months, a total of 825 cardiovascular deaths and worsening HF events were observed in the finerenone group, compared with 1012 events in the placebo group. The win ratio was 1.17 (95% confidence interval [CI] 1.04-1.32) (p = 0.010), demonstrating more wins than losses in the finerenone group. The win odds, corresponding to the treatment effect, was 1.05 (95% CI 1.01-1.09), and the net benefit, corresponding to the absolute risk difference, was 2.6% (95% CI 0.6-4.5%). The win ratio remained above 1.0 from 60 days after randomization and reached a plateau after approximately 12 months. HF hospitalizations contributed more to the overall results than cardiovascular death. The win odds at 12 months was 1.04 (95% CI 1.01-1.08), and when adding the Kansas City Cardiomyopathy Questionnaire total symptom score to the hierarchical endpoint as a continuous variable, that increased to 1.07, which is almost identical to the win ratio due to the decrease in ties. CONCLUSION: Finerenone treatment led to a significant improvement in a composite hierarchical outcome that incorporated cardiovascular death, total HF hospitalizations, and total urgent HF visits, with early onset of benefit. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT04435626.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Effect of finerenone on the hierarchical composite endpoint at 24 months. The figure shows the effect of finerenone on the hierarchical composite endpoint evaluated by win statistics. Win statistics with 95% confidence interval (CI) are described. The horizontal bars at the top of the figure show the overall percentages of wins, losses, and ties in the finerenone group for the hierarchical composite endpoint. The groups of coloured bars below show the percentages of wins and losses for each tier included in the hierarchical composite endpoint. HF, heart failure.
非 KM Figure
Figure 2Figure 2 Effect of finerenone on the hierarchical composite endpoint with and without the Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ‐TSS) (12‐month data). The figure shows the effects of finerenone on the hierarchical composite endpoint in the models incorporating KCCQ (third, fourth, and fifth models) and the model without KCCQ‐TSS (second model). The KCCQ‐TSS component was included as a dichotomous variable (≥10‐point improvement, followed by ≥5‐point deterioration); as both a dichotomous variable (tier 4) and a continuous variable (tier 5, model 4); or just as a continuous variable (model 5). Win statistics with 95% confidence interval (CI) are described. The horizontal bars at the top of the figure show the overall percentages of wins, losses, and ties in the finerenone group for the hierarchical composite endpoint. The groups of coloured bars below show the percentages of wins and losses for each tier included in the hierarchical composite endpoint. HF, heart failure.
非 KM Figure
Figure 3Figure 3 Win statistics over time. For the main model (i.e. hierarchy of tier 1, cardiovascular death; tier 2, total heart failure [HF] hospitalizations; tier 3, total urgent HF visits)¸ the following were plotted for every 10‐day fixed follow‐up period: win ratio with 95% confidence interval (CI) ( A ), the win odds with 95% CI ( B ), and the percentages of wins and losses ( C ).
非 KM Figure
Figure 4Figure 4 Effect of finerenone on the hierarchical composite endpoint according to selected subgroups. This figure shows win ratios and the percentages of wins, losses, and ties in the main model according to selected subgroups of patients. Win ratio was stratified by geographic region and baseline left ventricular ejection fraction ( < 60% or ≥60%). ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; CI, confidence interval; eGFR, estimated glomerular filtration rate; HF, heart failure; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association; SGLT2i, sodium–glucose cotransporter 2 inhibitor. *Stratified only by left ventricular ejection fraction ( < 60% or ≥ 60%). † Including Oceania and others. ‡ Stratified only by geographic region.
非 KM Figure